Parkinson's Disease
Conditions
Brief summary
This is a Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions.
Detailed description
32 healthy male or female participants will be enrolled in 1 of 6 sequences (designated as 1 through 6, respectively) in an ascending fashion. Sequences 1, 3, 4, and 5 will have 5 participants each, and Sequences 2 and 6 will have 6 participants each. Each sequence will proceed through the three cross-overs (suspension-fasted, tablet-fed, and tablet-fasted) according to the schematic, with dosing to occur on Days 1 of Periods 1, 2, and 3. Participants in the fasted portion of each sequence will be dosed under overnight fasted conditions and will remain fasted for 4 hours post-dose. Water consumption is permitted as desired except for 1 hour before and after administration of the Study Drug. To assess the effect of food on CVN424 bioavailability in tablet formulation, the single dose will be administered after ingestion of a standardized high-fat, high-calorie meal according to FDA Guidance for Industry (Food-effect bioavailability and fed bioequivalence studies, Jun 2022). Participants for all sequences will be admitted to the study unit 1 day prior to dosing and remain in the unit for safety and pharmacokinetics (PK) assessments through 96 hours post-dose. The total confinement period will be 5 nights for each period unless extended at the discretion of the Investigator, e.g., for monitoring and/or management of adverse events (AEs). Once 96-hour post-dose PK has been collected, participants will be discharged from the unit for the remainder of the washout period and return the day prior for their next scheduled dosing period
Interventions
DRUGCVN424
150 mg of either tablet or suspension formulation
Sponsors
Cerevance Beta, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* In the Investigator's opinion, the participant can understand and sign the Informed Consent Form (ICF) and comply with all protocol requirements. * The participant is male or female adult who is 18 to 55 years of age, inclusive at the time of Screening. * Participant weighs at least 45 kilograms (kg) (99 pounds \[lbs\]) and has a BMI between 18.0 and 35.0 kg/m2, inclusive at Screening. * The participant is medically healthy with no clinically significant (CS) or relevant abnormalities in medical history, physical exam, vital signs, ECG, and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigator. * Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to either remain abstinent or use two methods of adequate and reliable contraception (see Section 9.1.12) throughout the study and at least 12 weeks after the last dose of study drug has been taken.
Exclusion criteria
* Vegetarian, Vegan, Lactose intolerant, or follows a Kosher diet. * Evidence of clinically significant neurologic or other disorder or impairment that, in the opinion of the Investigator, is reasonably expected to impact the ability of the participant to participate or confound the study results. * A current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, any surgical intervention known to impact absorption \[e.g., bariatric surgery or bowel resection\]). Note, history of cholecystectomy is permitted if there is no evidence of malabsorption per the Investigator. * A history of cancer or other malignancy, with the exception of low-grade cervical intraepithelial neoplasia, low-grade (low-risk) prostate cancer, or 5-year cancer-free survivors of basal or squamous cell carcinoma or higher-grade cervical intraepithelial neoplasia or prostate cancer. * A positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or a human immunodeficiency virus (HIV) infection at Screening. * Any clinically significant abnormalities in labs: biochemistry (including liver function test \[LFT\], estimated glomerular filtration rate \[eGFR\], and glucose), hematology with white blood cell (WBC) differential, c-reactive protein (CRP), coagulation tests, lipase, amylase, albumin, and calcium. * A supine blood pressure outside the ranges of 80 to 160 mm Hg for systolic and 50 to 100 mm Hg for diastolic, confirmed with up to two repeat tests at the Screening Visit; or symptomatic orthostatic hypotension, in the opinion of the Investigator. * A resting heart rate outside the range of 40 to 100 beats per minute (bpm) confirmed with up to two repeat tests at the Screening Visit. Note that 40-50 and 90-100 bpm may be permitted only at the discretion of the Investigator. * Positive urine result for illegal drugs at Screening and Check-In, or history of illicit drug use or alcohol abuse within 1 year prior to the Screening Visit. * Received any investigational compound (defined as a drug that has not been FDA-approved) within 30 days prior to the first dose of study medication or within 5 half-lives of the investigational compound, whichever is greater. * Within 14 or 28 days prior to randomization, ingested any of the following excluded medication, supplements, or food products: St. John's wort, ginseng, kava, Ginkgo biloba, Chinese herbs, and melatonin, or known strong inhibitors/inducers of cytochrome P-4503A4/5, including rifampin, clarithromycin, ketoconazole, itraconazole. For full list of prohibited medications and dietary products, (See Table 2 in full protocol). * Regularly uses nicotine-containing products (including but not limited to cigarettes, electronic cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum). The casual users (≤ 10 cigarettes/week) may participate; however, they must agree to refrain from 30 days before Day 0 (Inpatient Check-in) for the duration of the study or a positive urine cotinine test at Inpatient Check-in. * Known history of coronary artery disease and hospitalization for myocardial infraction, ischemic heart disease, or congestive heart failure within the 2 years prior to the screening visit. * Any clinically significant medical, psychiatric, or laboratory abnormality that, in the judgment of the Investigator, is likely to interfere with study participation. * A history of major depression or risk of suicide according to the Investigator's clinical judgment or has made a suicide attempt. * Is a study site employee or an immediate family member of a study site employee.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Area Under the Plasma Concentration Time Curve From Time 0 to 96 Hours (AUC 0-96h) of CVN424 Suspension Fasted and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Maximum Observed Plasma Concentration (Cmax) of CVN424 Suspension Fasted and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Time to Reach Cmax (Tmax) of CVN424 Suspension and Tablet | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Time Taken for Drug to Appear in Systemic Circulation Following Administration (Tlag) of CVN424 Suspension and Tablet | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC(0-t) of CVN424 Tablet Fed and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) | Up to Day 35 | An adverse event is any untoward medical occurrence in a clinical research study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug. |
| AUC(0-96 Hrs) of CVN424 Tablet Fed and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Cmax of CVN424 Tablet Fed and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Tmax of CVN424 Tablet Fed and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
| Tlag of CVN424 Tablet Fed and Tablet Fasted | Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose | Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis. |
Countries
United States
Participant flow
Recruitment details
This was an Open-label, single oral dose, 3-way cross-over trial that evaluated the relative bioavailability of CVN424 suspension and tablet formulations and also included the assessment of the effect of food on the tablet formulation in healthy adult volunteers.
Pre-assignment details
A total of 32 participants entered the study and were randomized per protocol to 6 treatment sequences.
Participants by arm
| Arm | Count |
|---|---|
| Treatment Sequence ABC Participants were randomized to receive single oral dose of CVN424 150 milligrams (mg) on Day 1 of each treatment period in the following sequence: Treatment A: CVN424 150 mg suspension (fasted) in period 1; Treatment B: CVN424 150 mg Tablet (fasted) in period 2 and Treatment C: CVN424 150 mg Tablet (fed) in Treatment period 3. There was a washout period of 14 days between each treatment period. | 5 |
| Treatment Sequence ACB Participants were randomized to receive single oral dose of CVN424 150 mg on Day 1 of each treatment period in the following sequence: Treatment A: CVN424 150 mg suspension (fasted) in period 1; Treatment C: CVN424 150 mg Tablet (fed) in Treatment period 2 and Treatment B: CVN424 150 mg Tablet (fasted) in period 3. There was a washout period of 14 days between each treatment period. | 5 |
| Treatment Sequence BAC Participants were randomized to receive single oral dose of CVN424 150 mg on Day 1 of each treatment period in the following sequence: Treatment B: CVN424 150 mg Tablet (fasted) in period 1; Treatment A: CVN424 150 mg suspension (fasted) in Treatment period 2 and Treatment C: CVN424 150 mg Tablet (fed) in period 3. There was a washout period of 14 days between each treatment period. | 5 |
| Treatment Sequence BCA Participants were randomized to receive single oral dose of CVN424 150 milligrams (mg) on Day 1 of each treatment period in the following sequence: Treatment B: CVN424 150 mg Tablet (fasted) in period 1; Treatment C: CVN424 150 mg Tablet (fed) in period 2 and Treatment A: CVN424 150 mg suspension (fasted) in Treatment period 3. There was a washout period of 14 days between each treatment period. | 6 |
| Treatment Sequence CAB Participants were randomized to receive single oral dose of CVN424 150 mg on Day 1 of each treatment period in the following sequence: Treatment C: CVN424 150 mg Tablet (fed) in Treatment period 1; Treatment A: CVN424 150 mg suspension (fasted) in period 2 and Treatment B: CVN424 150 mg Tablet (fasted) in period 3. There was a washout period of 14 days between each treatment period. | 5 |
| Treatment Sequence CBA Participants were randomized to receive single oral dose of CVN424 150 mg on Day 1 of each treatment period in the following sequence: Treatment C: CVN424 150 mg Tablet (fed) in Treatment period 1; Treatment B: CVN424 150 mg Tablet (fasted) in period 2 and Treatment A: CVN424 150 mg suspension (fasted) in period 3. There was a washout period of 14 days between each treatment period. | 6 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Period 2: Dosing 2 (Day 1) | Lost to Follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Period 3: Dosing 3 (Day 1) | Adverse Event | 0 | 0 | 0 | 1 | 0 | 0 |
| Period 3: Dosing 3 (Day 1) | Failed Check-In Laboratory | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Treatment Sequence ABC | Treatment Sequence ACB | Treatment Sequence BAC | Treatment Sequence BCA | Treatment Sequence CAB | Treatment Sequence CBA | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 36.6 Years STANDARD_DEVIATION 9.07 | 36.0 Years STANDARD_DEVIATION 8.94 | 39.6 Years STANDARD_DEVIATION 10.11 | 38.2 Years STANDARD_DEVIATION 7.11 | 37.6 Years STANDARD_DEVIATION 12.54 | 48.0 Years STANDARD_DEVIATION 3.29 | 39.6 Years STANDARD_DEVIATION 9.09 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 4 Participants | 5 Participants | 4 Participants | 2 Participants | 4 Participants | 22 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 1 Participants | 0 Participants | 2 Participants | 3 Participants | 2 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 3 Participants | 5 Participants | 6 Participants | 3 Participants | 5 Participants | 24 Participants |
| Sex: Female, Male Female | 2 Participants | 4 Participants | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 18 Participants |
| Sex: Female, Male Male | 3 Participants | 1 Participants | 2 Participants | 3 Participants | 2 Participants | 3 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 30 | 0 / 30 | 0 / 32 |
| other Total, other adverse events | 8 / 30 | 11 / 30 | 11 / 32 |
| serious Total, serious adverse events | 0 / 30 | 0 / 30 | 0 / 32 |
Outcome results
Primary
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set consists of all participants who received study drug and had at least 1 measurable plasma concentration. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted | 16790 Hours*nanograms per milliliter | Geometric Coefficient of Variation 19.3 |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted | 10100 Hours*nanograms per milliliter | Geometric Coefficient of Variation 31.8 |
90% CI: [56.12, 64.42]
Primary
Area Under the Plasma Concentration Time Curve From Time 0 to 96 Hours (AUC 0-96h) of CVN424 Suspension Fasted and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Area Under the Plasma Concentration Time Curve From Time 0 to 96 Hours (AUC 0-96h) of CVN424 Suspension Fasted and Tablet Fasted | 16780 Hours*nanograms per milliliter | Geometric Coefficient of Variation 19.3 |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Area Under the Plasma Concentration Time Curve From Time 0 to 96 Hours (AUC 0-96h) of CVN424 Suspension Fasted and Tablet Fasted | 10100 Hours*nanograms per milliliter | Geometric Coefficient of Variation 31.8 |
90% CI: [56.12, 64.42]
Primary
Maximum Observed Plasma Concentration (Cmax) of CVN424 Suspension Fasted and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Maximum Observed Plasma Concentration (Cmax) of CVN424 Suspension Fasted and Tablet Fasted | 812.9 nanograms per milliliter | Geometric Coefficient of Variation 28.9 |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Maximum Observed Plasma Concentration (Cmax) of CVN424 Suspension Fasted and Tablet Fasted | 231.1 nanograms per milliliter | Geometric Coefficient of Variation 40.6 |
90% CI: [25.09, 31.13]
Primary
Time Taken for Drug to Appear in Systemic Circulation Following Administration (Tlag) of CVN424 Suspension and Tablet
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Time Taken for Drug to Appear in Systemic Circulation Following Administration (Tlag) of CVN424 Suspension and Tablet | 0.00 hours |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Time Taken for Drug to Appear in Systemic Circulation Following Administration (Tlag) of CVN424 Suspension and Tablet | 0.00 hours |
| Treatment C: CVN424 150 mg Tablet (Fed) | Time Taken for Drug to Appear in Systemic Circulation Following Administration (Tlag) of CVN424 Suspension and Tablet | 0.00 hours |
90% CI: [0, 0]
p-value: 0.00190% CI: [0, 0.251]ANOVA
Primary
Time to Reach Cmax (Tmax) of CVN424 Suspension and Tablet
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Time to Reach Cmax (Tmax) of CVN424 Suspension and Tablet | 2.040 hours |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Time to Reach Cmax (Tmax) of CVN424 Suspension and Tablet | 3.526 hours |
| Treatment C: CVN424 150 mg Tablet (Fed) | Time to Reach Cmax (Tmax) of CVN424 Suspension and Tablet | 4.055 hours |
p-value: <0.000190% CI: [0.9265, 2.247]ANOVA
p-value: <0.000190% CI: [2.4475, 3.0035]ANOVA
Secondary
AUC(0-96 Hrs) of CVN424 Tablet Fed and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | AUC(0-96 Hrs) of CVN424 Tablet Fed and Tablet Fasted | 10100 Hours*nanograms per milliliter | Geometric Coefficient of Variation 31.8 |
| Treatment B: CVN424 150 mg Tablet (Fasted) | AUC(0-96 Hrs) of CVN424 Tablet Fed and Tablet Fasted | 16340 Hours*nanograms per milliliter | Geometric Coefficient of Variation 20 |
90% CI: [150.98, 172.95]
Secondary
AUC(0-t) of CVN424 Tablet Fed and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | AUC(0-t) of CVN424 Tablet Fed and Tablet Fasted | 10100 Hours*nanograms per milliliter | Geometric Coefficient of Variation 31.8 |
| Treatment B: CVN424 150 mg Tablet (Fasted) | AUC(0-t) of CVN424 Tablet Fed and Tablet Fasted | 16340 Hours*nanograms per milliliter | Geometric Coefficient of Variation 20 |
90% CI: [150.96, 172.92]
Secondary
Cmax of CVN424 Tablet Fed and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Cmax of CVN424 Tablet Fed and Tablet Fasted | 231.1 Nanograms per milliliter | Geometric Coefficient of Variation 40.6 |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Cmax of CVN424 Tablet Fed and Tablet Fasted | 693.8 Nanograms per milliliter | Geometric Coefficient of Variation 23.5 |
90% CI: [273.51, 338.31]
Secondary
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
An adverse event is any untoward medical occurrence in a clinical research study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug.
Time frame: Up to Day 35
Population: Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) | 8 Participants |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) | 11 Participants |
| Treatment C: CVN424 150 mg Tablet (Fed) | Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) | 11 Participants |
Secondary
Tlag of CVN424 Tablet Fed and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Tlag of CVN424 Tablet Fed and Tablet Fasted | 0.00 hours |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Tlag of CVN424 Tablet Fed and Tablet Fasted | 0.00 hours |
p-value: 0.003990% CI: [0, 0.251]ANOVA
Secondary
Tmax of CVN424 Tablet Fed and Tablet Fasted
Blood samples were collected at indicated time points for PK analysis of CVN424 tablet. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60,72, 84 and 96 hours post-dose
Population: PK Analysis Set. Only those participants with data available at specified timepoints have been presented.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment A: CVN424 150 mg Suspension (Fasted) | Tmax of CVN424 Tablet Fed and Tablet Fasted | 3.526 hours |
| Treatment B: CVN424 150 mg Tablet (Fasted) | Tmax of CVN424 Tablet Fed and Tablet Fasted | 4.055 hours |
p-value: 0.066290% CI: [0.006, 1.537]ANOVA